Phosphodiesterase-5 inhibitors for the treatment of secondary Raynaud's phenomenon:
systematic review and meta-analysis of randomised trials

Roustit M, Blaise S, Allanore Y, Carpentier PH, Caglayan E, Cracowski JL

Record Status
This is a systematic review that meets the criteria for inclusion on DARE.

Bibliographic details
Roustit M, Blaise S, Allanore Y, Carpentier PH, Caglayan E, Cracowski JL. Phosphodiesterase-5 inhibitors for the
treatment of secondary Raynaud's phenomenon: systematic review and meta-analysis of randomised trials. Annals of
the Rheumatic Diseases 2013; 72(10): 1696-1699

PubMedID
23426043

DOI
10.1136/annrheumdis-2012-202836

Indexing Status
Subject indexing assigned by NLM

MeSH
Carbolines /therapeutic use; Humans; Imidazoles /therapeutic use; Phosphodiesterase 5 Inhibitors /therapeutic use;
Piperazines /therapeutic use; Purines /therapeutic use; Randomized Controlled Trials as Topic; Raynaud Disease /drug
therapy; Sildenafil Citrate; Sulfones /therapeutic use; Tadalafil; Treatment Outcome; Triazines /therapeutic use;
Vardenafil Dihydrochloride

AccessionNumber
12013059018

Date bibliographic record published
23/10/2013